HRP20030652A2 - Method of treating of demyelinating diseases or conditions - Google Patents

Method of treating of demyelinating diseases or conditions Download PDF

Info

Publication number: HRP20030652A2
Authority: HR; Croatia
Prior art keywords: hydrogen; compound; c6alkyl; alkyl; treatment
Prior art date: 2001-02-15

Application number

HR20030652A

Other languages

English (en)

Croatian (hr)

Inventor

P. Smith Craig

P. Rathbone Michel

Petty Margaret

Rampe David

Original Assignee

Aventis Pharmaceuticals Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-15

Filing date

2002-02-14

Publication date

2005-06-30

2002-02-14 Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.

2005-06-30 Publication of HRP20030652A2 publication Critical patent/HRP20030652A2/hr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

HR20030652A 2001-02-15 2002-02-14 Method of treating of demyelinating diseases or conditions HRP20030652A2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US26884601P	2001-02-15	2001-02-15
GBGB0119435.6A GB0119435D0 (en)	2001-02-15	2001-08-09	Method of treating of demyelinating diseases or conditions
PCT/US2002/005501 WO2002064126A2 (fr)	2001-02-15	2002-02-14	Methode destinee au traitement de pathologies ou de troubles lies a la demyelinisation

Publications (1)

Publication Number	Publication Date
HRP20030652A2 true HRP20030652A2 (en)	2005-06-30

Family

ID=23024747

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20030652A HRP20030652A2 (en)	2001-02-15	2002-02-14	Method of treating of demyelinating diseases or conditions

Country Status (39)

Country	Link
US (10)	US6967210B2 (fr)
EP (1)	EP1368031A2 (fr)
JP (3)	JP2004518711A (fr)
KR (3)	KR20090005254A (fr)
CN (2)	CN100522164C (fr)
AP (1)	AP1749A (fr)
AR (1)	AR035750A1 (fr)
AU (3)	AU2002247200B9 (fr)
BR (1)	BR0207272A (fr)
CA (1)	CA2438712A1 (fr)
CO (1)	CO5390085A1 (fr)
CR (1)	CR7023A (fr)
CZ (1)	CZ20032172A3 (fr)
EA (2)	EA011319B1 (fr)
EC (1)	ECSP024218A (fr)
EE (1)	EE200300363A (fr)
GB (1)	GB0119435D0 (fr)
HK (1)	HK1080361B (fr)
HR (1)	HRP20030652A2 (fr)
HU (1)	HUP0303203A3 (fr)
IL (2)	IL157341A0 (fr)
MA (1)	MA26152A1 (fr)
ME (1)	MEP21208A (fr)
MX (1)	MXPA03006110A (fr)
MY (1)	MY157745A (fr)
NO (1)	NO20033622L (fr)
NZ (4)	NZ527011A (fr)
OA (1)	OA12549A (fr)
PA (1)	PA8540101A1 (fr)
PE (1)	PE20040175A1 (fr)
PL (1)	PL363638A1 (fr)
SG (1)	SG134170A1 (fr)
SK (1)	SK10392003A3 (fr)
TR (4)	TR200301330T2 (fr)
TW (1)	TWI325319B (fr)
UA (2)	UA80394C2 (fr)
WO (1)	WO2002064126A2 (fr)
YU (1)	YU62903A (fr)
ZA (1)	ZA200306124B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0119435D0 (en) *	2001-02-15	2001-10-03	Aventis Pharm Prod Inc	Method of treating of demyelinating diseases or conditions
ES2288641T3 (es) *	2002-12-20	2008-01-16	Dynogen Pharmaceuticals Inc.	Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
EP1589959A2 (fr) *	2003-01-30	2005-11-02	Dynogen Pharmaceuticals Inc.	Methodes destinees a traiter les troubles du tractus urinaire inferieur au moyen de modulateurs du canal sodique
DE602004003172T2 (de) *	2003-03-21	2007-09-27	Dynogen Pharmaceuticals Inc., Waltham	Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
GT200500063A (es) *	2004-04-01	2005-10-14		Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) *	2005-04-28	2005-06-22	Paradigm Therapeutics Ltd	Ion channel
FR2892021B1 (fr) *	2005-10-19	2008-01-04	Urogene	Traitement de l'incontinence urinaire d'effort et mixte
FR2892022B1 (fr) *	2005-10-19	2008-01-04	Urogene Sa	Traitement des symptomes de l'irritation de la vessie
US8420593B1 (en) *	2006-06-16	2013-04-16	Landon C. G. Miller	Compositions and methods for regulating membrane potential
DE102008044844B4 (de) *	2008-08-28	2018-08-30	Siemens Healthcare Gmbh	Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
WO2011118364A1 (fr) *	2010-03-26	2011-09-29	Semiconductor Energy Laboratory Co., Ltd.	Dispositif semi-conducteur
WO2012009204A1 (fr) *	2010-07-15	2012-01-19	The Trustees Of Columbia University In The City Of New York	Procédés pour le diagnostic et le traitement de troubles commotionnels
JP2014503596A (ja) *	2011-01-28	2014-02-13	アコーダセラピューティクス，インコーポレーテッド	脳性麻痺を治療するためのカリウムチャネル遮断薬の使用
TWI592156B (zh) *	2011-10-04	2017-07-21	艾可達醫療公司	使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
WO2017151409A1 (fr)	2016-02-29	2017-09-08	University Of Florida Research Foundation, Incorporated	Méthodes de chimiothérapie
US11730769B2 (en)	2017-12-22	2023-08-22	Children's Medical Center Corporation	Compositions and methods for Williams Syndrome (WS) therapy
CN116723870A (zh) *	2021-01-20	2023-09-08	拉什大学医学中心	球形细胞脑白质营养不良症或克拉伯病的改良治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4970218A (en) *	1987-04-24	1990-11-13	Hoechst-Roussel Pharmaceuticals Inc.	N-(pyridinyl)-1H-indol-1-amines
ATE115143T1 (de) *	1987-04-24	1994-12-15	Hoechst Roussel Pharma	N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
US4880822A (en) *	1987-04-24	1989-11-14	Hoechst-Roussel Pharmaceuticals, Inc.	N-(pyridinyl)-1H-indol-1-amines
DK0415103T3 (da)	1989-08-02	1995-06-19	Hoechst Roussel Pharma	2,3-Dihydro-1-(pyridinylamino)-indoler, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
US5214038A (en) *	1991-04-15	1993-05-25	Hoechst-Roussel Pharmaceuticals Inc.	1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) *	1993-07-29	1995-02-02	Boehringer Ingelheim Kg	Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en)	1994-05-13	1995-10-17	Hoechst-Roussel Pharmaceuticals Inc.	Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en)	1994-11-08	1996-10-15	Muhlhauser; Mark A.	Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (fr)	1995-03-10	1996-09-11	Boehringer Mannheim Gmbh	Procédé de fabrication d'un agent thérapeutique pour la régénération d'oligodendrocytes
FR2754147B1 (fr)	1996-10-03	2000-02-04	Mbh Technologies Sa	Installation et procede pour le traitement de carcasses
PT1056754E (pt) *	1998-01-29	2004-03-31	Bristol Myers Squibb Co	Derivados fosfatados de 1,3,4-oxadiazolona de diarilo
AU5483500A (en)	1999-07-09	2001-01-30	Ortho-Mcneil Pharmaceutical, Inc.	Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) *	2001-02-15	2001-10-03	Aventis Pharm Prod Inc	Method of treating of demyelinating diseases or conditions

2001
- 2001-08-09 GB GBGB0119435.6A patent/GB0119435D0/en not_active Ceased
2002
- 2002-02-14 SG SG200505802-9A patent/SG134170A1/en unknown
- 2002-02-14 CZ CZ20032172A patent/CZ20032172A3/cs unknown
- 2002-02-14 NZ NZ527011A patent/NZ527011A/en unknown
- 2002-02-14 TR TR2003/01330T patent/TR200301330T2/xx unknown
- 2002-02-14 EP EP02714974A patent/EP1368031A2/fr not_active Withdrawn
- 2002-02-14 KR KR1020087031854A patent/KR20090005254A/ko not_active Ceased
- 2002-02-14 CN CNB2005100597348A patent/CN100522164C/zh not_active Expired - Fee Related
- 2002-02-14 UA UA2003098376A patent/UA80394C2/uk unknown
- 2002-02-14 AP APAP/P/2003/002834A patent/AP1749A/en active
- 2002-02-14 EA EA200300882A patent/EA011319B1/ru not_active IP Right Cessation
- 2002-02-14 KR KR1020087031855A patent/KR100951542B1/ko not_active Expired - Fee Related
- 2002-02-14 MX MXPA03006110A patent/MXPA03006110A/es active IP Right Grant
- 2002-02-14 CN CNA028048644A patent/CN1529598A/zh active Pending
- 2002-02-14 OA OA1200300199A patent/OA12549A/en unknown
- 2002-02-14 IL IL15734102A patent/IL157341A0/xx unknown
- 2002-02-14 HU HU0303203A patent/HUP0303203A3/hu unknown
- 2002-02-14 SK SK1039-2003A patent/SK10392003A3/sk unknown
- 2002-02-14 KR KR1020037010691A patent/KR100951540B1/ko not_active Expired - Fee Related
- 2002-02-14 TR TR2008/00692T patent/TR200800692T2/xx unknown
- 2002-02-14 NZ NZ544720A patent/NZ544720A/en unknown
- 2002-02-14 HR HR20030652A patent/HRP20030652A2/hr not_active Application Discontinuation
- 2002-02-14 TR TR2008/00693T patent/TR200800693T2/xx unknown
- 2002-02-14 WO PCT/US2002/005501 patent/WO2002064126A2/fr not_active Ceased
- 2002-02-14 ME MEP-212/08A patent/MEP21208A/xx unknown
- 2002-02-14 YU YU62903A patent/YU62903A/sh unknown
- 2002-02-14 NZ NZ539159A patent/NZ539159A/en unknown
- 2002-02-14 US US10/076,191 patent/US6967210B2/en not_active Expired - Lifetime
- 2002-02-14 AU AU2002247200A patent/AU2002247200B9/en not_active Ceased
- 2002-02-14 CA CA002438712A patent/CA2438712A1/fr not_active Abandoned
- 2002-02-14 PL PL02363638A patent/PL363638A1/xx not_active Application Discontinuation
- 2002-02-14 JP JP2002563920A patent/JP2004518711A/ja not_active Ceased
- 2002-02-14 TR TR2008/00691T patent/TR200800691T2/xx unknown
- 2002-02-14 BR BR0207272-6A patent/BR0207272A/pt not_active IP Right Cessation
- 2002-02-14 EA EA200600896A patent/EA012409B1/ru not_active IP Right Cessation
- 2002-02-14 NZ NZ556697A patent/NZ556697A/en unknown
- 2002-02-14 EE EEP200300363A patent/EE200300363A/xx unknown
- 2002-02-15 MY MYPI20020518A patent/MY157745A/en unknown
- 2002-02-15 AR ARP020100540A patent/AR035750A1/es unknown
- 2002-02-15 EC EC2002004218A patent/ECSP024218A/es unknown
- 2002-02-15 CO CO02013025A patent/CO5390085A1/es not_active Application Discontinuation
- 2002-02-15 TW TW091102861A patent/TWI325319B/zh not_active IP Right Cessation
- 2002-02-18 PA PA20028540101A patent/PA8540101A1/es unknown
- 2002-02-26 PE PE2002000159A patent/PE20040175A1/es not_active Application Discontinuation
2003
- 2003-07-11 MA MA27235A patent/MA26152A1/fr unknown
- 2003-07-16 CR CR7023A patent/CR7023A/es unknown
- 2003-08-07 ZA ZA200306124A patent/ZA200306124B/xx unknown
- 2003-08-11 IL IL157341A patent/IL157341A/en not_active IP Right Cessation
- 2003-08-14 NO NO20033622A patent/NO20033622L/no not_active Application Discontinuation
2004
- 2004-02-03 US US10/770,656 patent/US20040157889A1/en not_active Abandoned
- 2004-02-03 US US10/770,655 patent/US20040157888A1/en not_active Abandoned
2005
- 2005-03-14 US US11/079,327 patent/US7230015B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/079,366 patent/US7179821B2/en not_active Expired - Lifetime
- 2005-09-27 US US11/236,145 patent/US7534803B2/en not_active Expired - Fee Related
2006
- 2006-01-05 HK HK06100186.8A patent/HK1080361B/zh not_active IP Right Cessation
- 2006-04-04 UA UAA200603708A patent/UA88773C2/ru unknown
2008
- 2008-03-13 AU AU2008201179A patent/AU2008201179B2/en not_active Ceased
2009
- 2009-04-06 JP JP2009091807A patent/JP2009185045A/ja not_active Abandoned
- 2009-04-29 US US12/420,381 patent/US20090270458A1/en not_active Abandoned
- 2009-04-29 US US12/420,407 patent/US20090209594A1/en not_active Abandoned
- 2009-04-29 US US12/420,390 patent/US20090281147A1/en not_active Abandoned
- 2009-04-29 US US12/420,416 patent/US20090209595A1/en not_active Abandoned
- 2009-11-19 AU AU2009238332A patent/AU2009238332A1/en not_active Abandoned
2010
- 2010-02-16 JP JP2010030929A patent/JP2010120958A/ja not_active Abandoned

Also Published As

Publication number	Publication date
KR20040014459A (ko)	2004-02-14
CZ20032172A3 (cs)	2004-01-14
MEP21208A (en)	2010-06-10
EA200300882A1 (ru)	2003-12-25
US20050234105A1 (en)	2005-10-20
IL157341A (en)	2010-11-30
MXPA03006110A (es)	2005-07-01
KR20090005254A (ko)	2009-01-12
EE200300363A (et)	2003-10-15
US20060025452A1 (en)	2006-02-02
CR7023A (es)	2003-11-17
AU2008201179B2 (en)	2009-08-20
AP1749A (en)	2007-06-13
MY157745A (en)	2016-07-15
TR200800692T2 (tr)	2008-03-21
US20040157888A1 (en)	2004-08-12
HK1080361B (zh)	2009-10-30
NO20033622L (no)	2003-10-06
US7179821B2 (en)	2007-02-20
MA26152A1 (fr)	2004-07-01
JP2009185045A (ja)	2009-08-20
PE20040175A1 (es)	2004-03-29
US20050159456A1 (en)	2005-07-21
IL157341A0 (en)	2004-02-19
US20090270458A1 (en)	2009-10-29
US20090209595A1 (en)	2009-08-20
KR100951540B1 (ko)	2010-04-09
NZ539159A (en)	2006-11-30
HK1080361A1 (zh)	2006-04-28
CO5390085A1 (es)	2004-04-30
EA011319B1 (ru)	2009-02-27
US20040157889A1 (en)	2004-08-12
WO2002064126A2 (fr)	2002-08-22
YU62903A (sh)	2006-05-25
EA012409B1 (ru)	2009-10-30
UA80394C2 (en)	2007-09-25
CA2438712A1 (fr)	2002-08-22
AU2002247200B9 (en)	2008-07-10
JP2010120958A (ja)	2010-06-03
AU2008201179A1 (en)	2008-04-03
US20090209594A1 (en)	2009-08-20
NO20033622D0 (no)	2003-08-14
AU2009238332A1 (en)	2009-12-10
WO2002064126A3 (fr)	2003-02-20
EP1368031A2 (fr)	2003-12-10
AP2003002834A0 (en)	2003-09-30
SK10392003A3 (sk)	2004-01-08
TWI325319B (en)	2010-06-01
EA200600896A1 (ru)	2006-08-25
US7534803B2 (en)	2009-05-19
CN1679564A (zh)	2005-10-12
CN1529598A (zh)	2004-09-15
TR200800691T2 (tr)	2008-03-21
PA8540101A1 (es)	2003-09-05
GB0119435D0 (en)	2001-10-03
JP2004518711A (ja)	2004-06-24
US7230015B2 (en)	2007-06-12
HUP0303203A2 (hu)	2003-12-29
ZA200306124B (en)	2004-11-08
HUP0303203A3 (en)	2007-11-28
US20090281147A1 (en)	2009-11-12
OA12549A (en)	2006-06-05
ECSP024218A (es)	2003-09-24
UA88773C2 (ru)	2009-11-25
KR100951542B1 (ko)	2010-04-09
NZ544720A (en)	2007-08-31
SG134170A1 (en)	2007-08-29
PL363638A1 (en)	2004-11-29
KR20090005255A (ko)	2009-01-12
AR035750A1 (es)	2004-07-07
NZ527011A (en)	2005-07-29
US20030105150A1 (en)	2003-06-05
CN100522164C (zh)	2009-08-05
US6967210B2 (en)	2005-11-22
BR0207272A (pt)	2004-02-10
AU2002247200B2 (en)	2007-12-13
TR200301330T2 (tr)	2004-12-21
NZ556697A (en)	2009-01-31
TR200800693T2 (tr)	2008-07-21

Legal Events

Date	Code	Title	Description
2005-06-30	A1OB	Publication of a patent application
2005-12-27	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2010-02-13	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20100213 Year of fee payment: 9
2012-02-24	OBST	Application withdrawn

Publication	Publication Date	Title
AU2008201179B2 (en)	2009-08-20	Method of treating of demyelinating diseases or conditions
AU2002247200A1 (en)	2003-02-20	Method of treating of demyelinating diseases or conditions
DE3530767C2 (fr)	1989-03-16
Ishida et al.	1992	Comparing the anticonvulsive effects of dapsone on amygdala‐kindled seizures and hippocampal‐kindled seizures in rats
CZ312894A3 (en)	1995-07-12	Use of isethionate of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for preparing a medicament used for treating and prevention of dependence, tolerance and response to drugs